Auto-updatedIndexed records3,975Updated Jul 3, 2026 01:22 UTC
Psilocybin Research Publication Tracker
Search, analyze, export, and monitor psilocybin and psilocin literature across peer-reviewed papers, preprints, reviews, protocols, and clinical trials.
Database up to dateLast update: Jul 3, 2026 01:22 UTC
Background and aimsAustralia recently down-scheduled and authorised psychedelic-assisted therapies, including psilocybin, for certain mental health conditions. Evidence is emerging for potential application in substance use disorder treatment. However, regulatory developments have outpaced implementation readiness. While service leaders and clinicians are cr...
Background: Self-stigma refers to the internalization of negative societal beliefs and has been associated with reduced self-efficacy, self-esteem and treatment avoidance among substance users. However, little research has explored antecedents of self-stigma such as substance use motives. This may be particularly salient for psilocybin which is used both as ...
The use of psychedelics in the treatment of psychopathologies has been expanding, highlighting Psychedelic-Assisted Psychotherapy (PAP) as a promising resource in mental health care. This systematic review investigates. This systematic review investigates whether and how cognitive-behavioral therapies are integrated with psychedelic substances-both classical...
Unknown journal2026-03-27Varela YM, de O Tavares VD, Delgado LM, de Faria HAT, Menezes LQ, Almeida RM, Agrícola P, de Carvalho BS, Bienemann B, Falchi-Carvalho M, Cavalcanti-Ribeiro P, Palhano-Fontes F, Fernandes-Osterhold G, de Araujo DB, Galvão-Coelho N.
Europe PMCPublishedpsilocybinClinical TrialSystematic ReviewReview ArticleSystematic Review
This Phase 2a pilot, exploratory, randomized, double-blind, placebo-controlled, parallel-group trial will estimate whether concurrent fluoxetine alters the antidepressant effect, acute psychedelic experience, or safety of a psychedelic-assisted psychotherapy session in adults with treatment-resistant major depressive disorder (TRD). Eligible participants (ag...
ClinicalTrials.gov2026-03-26Federal University of Latin American Integration
ClinicalTrials.govCLINICAL TRIALpsilocybinDepressionClinical TrialTreatment-Resistant DepressionSafetyClinical TrialDepressive DisorderPsilocybin and Psilocyn
Psilocybin is studied as innovative medication in anxiety, substance abuse and treatment-resistant depression. Animal studies show that psychedelics promote neuronal plasticity by strengthening synaptic responses and protein synthesis. However, the exact molecular and cellular changes induced by psilocybin in the human brain are not known. Here, we treated h...
Psilocybin is studied as innovative medication in anxiety, substance abuse and treatment-resistant depression. Animal studies show that psychedelics promote neuronal plasticity by strengthening synaptic responses and protein synthesis. However, the exact molecular and cellular changes induced by psilocybin in the human brain are not known. Here, we treated h...
Unknown journal2026-03-26Schmidt M, Hoffrichter A, Davoudi M, Horschitz S, Lau T, Meinhardt MW, Spanagel R, Ladewig J, Köhr G, Koch P.
Europe PMCPublishedpsilocybinpsilocinDepressionAnxietyNeuroplasticityReceptor PharmacologyBiomarkersTreatment-Resistant DepressionTranscriptomicsOtherCerebral CortexNeurons
Psilocybin can produce sustained benefits in affective and trauma-related disorders, yet if and how it reshapes sensory representations of learned valence associations remains largely unclear. To address this, we used longitudinal two-photon calcium imaging in awake C57BL/6 mice to examine how psilocybin modulates layer 2/3 auditory cortex activity at single...
Background: Psilocybin-assisted therapy (PAT) has shown promise for alcohol use disorder (AUD) in randomized controlled trials (RCTs). However, the effects of open-label administration following blinded treatment are unclear. Here, we present safety and efficacy data from an open-label extension of a Phase II RCT (NCT02061293) examining PAT for AUD. Methods:...
PsyArXiv2026-03-25Pagni BA, Ross S, Mennenga S, Bhatt SR, Zeifman R, Petridis P, Carrithers B, Worth L, Podrebarac S, Owens L, O'Donnell K, Roberts DE, Kim Y, Bogenschutz M.
Background: Psilocybin-assisted therapy (PAT) has shown promise for alcohol use disorder (AUD) in randomized controlled trials (RCTs). However, the effects of open-label administration following blinded treatment are unclear. Here, we present safety and efficacy data from an open-label extension of a Phase II RCT (NCT02061293) examining PAT for AUD. Methods:...
Uncovering the neural basis of psychedelics' potent effects on brain activity and conscious experience has great potential for understanding their therapeutic effects. Numerous studies using functional magnetic resonance imaging (fMRI) uncovered a strong effect of psychedelics on global properties of fMRI signal, but how they map to underlying neural phenome...
Background/Objectives: Psilocybin has re-emerged as a promising intervention for neuropsychiatric disorders including major depressive disorder, treatment-resistant depression, anxiety associated with life-threatening illness, obsessive compulsive disorder, and substance use disorders. However, conventional randomized controlled trials (RCTs)-the current gol...
Note: The trial is only eligible for citizens of Denmark. The purpose of this project is to assess the treatment efficacy of a single high dose of psilocybin administered within a protocol of psychological support to patients diagnosed with alcohol use disorder (AUD). To establish efficacy, we will investigate a single dose of psilocybin versus placebo in a ...
The goal of this clinical trial is to systematically categorize potential prohedonic effects of psilocybin in patients with anhedonia in depression. The main questions it aims to answer are: Primary Objectives 1. Systematically categorize prohedonic effects (antianhedonic effects in patients with anhedonia in depression, increase in well-being in all partici...
ClinicalTrials.gov2026-03-23Medical University of Vienna
ClinicalTrials.govCLINICAL TRIALpsilocybinDepressionNeuroplasticityBrain ImagingReceptor PharmacologyAgingWellbeingClinical TrialInflammationClinical TrialDepression - Major Depressive DisorderAnhedonia
Psilocybin, chemically known as (4-phosphoryloxy-N, N-dimethyltryptamine, 4-PODMT), is derived from the psychoactive mushroom genus, Psilocybe. Of the four active metabolites, psilocin readily enters systemic circulation. The psychoactive effects of psilocin are thought to arise through partial agonist effects at the 5-HT2A receptor. Psychedelic drugs, inclu...
Disorders of consciousness pose major therapeutic challenges owing to the complexity of underlying brain dysfunctions. Current pharmacological interventions explored in disorders of consciousness target distinct molecular systems, including dopaminergic modulators (amantadine, levodopa, apomorphine, bromocriptine, selegiline, methylphenidate, and modafinil),...
Unknown journal2026-03-23Gillet A, Geron C, Vitello MM, Lejeune N.
Europe PMCPublishedpsilocinAddictionBrain ImagingMechanism of ActionReceptor PharmacologyConsciousnessBiomarkersAgingReview ArticleSafetyReview ArticleAnimalsHumans
Serotonergic psychedelics have attracted considerable interest as promising therapeutic agents. However, the molecular mechanisms linking their acute hallucinogenic-like effects to longer-lasting neuroplastic responses remain incompletely understood, partly because of the scarcity of native neural models suitable for mechanistic studies. Here, we developed a...
IntroductionThe contribution of patient support to psilocybin's antidepressant effects remains uncertain.MethodsRelationships between therapeutic alliance (Scale to Assess Therapeutic Relationship-Patient version; STAR-P), psychedelic experience (Five-Dimensional Altered States of Consciousness Questionnaire and Emotional Breakthrough Inventory; 5D-ASC and E...
Unknown journal2026-03-22Goodwin GM, Aaronson ST, Alvarez O, Carhart-Harris R, Croal M, Feifel D, Hellerstein DJ, Husain MI, Kelly JR, Kirlic N, Licht RW, Marwood L, Nowakowska A, Páleníček T, Repantis D, Schoevers RA, Simmons H, Soares JC, Somers M, Tsai J, Wahba M, Williams E, Young AH, Young MB, Zisook S, Malievskaia E.
Europe PMCPublishedpsilocybinDepressionConsciousnessEmotional ProcessingTreatment-Resistant DepressionOtherHumansHallucinogens
Nach einer Pause gibt es heute wieder Evidenz-Quickies, und zwar gleich mehrere, dafür aber kürzer und weniger ausführlich als zuletzt. Und dieses Format ist jetzt zweigeteilt: (a) Für alle, denen die Nachricht genügt, gibt es oben die Quickies in Kürze. (b) Alle, die weiterlesen wollen, finden die detaillierten Fassungen unten. Viel Freude und hoffentlich i...
ObjectiveThis systematic review and meta-analysis of six randomized controlled trials aimed to investigate the temporal changes in the efficacy and safety of psilocybin treatment for major depressive disorder (MDD).MethodsSeparate meta-analyses were conducted for standard-dose psilocybin (25 mg/session, or 20-30 mg/70 kg/session) and low-dose psilocybin (10 ...
PRE-EMPT will assemble a study group of 150 civilian and Veteran participants from three populations (low risk, intermediate risk, and high risk for self-harm). The investigators will obtain clinical assessments, MRI, and blood levels for circular RNA (circRNA). The teams will then administer three interventions (neurofeedback, transcranial magnetic stimulat...
ClinicalTrials.gov2026-03-19University of New Mexico
ClinicalTrials.govCLINICAL TRIALpsilocybinDepressionPTSDNeuroplasticityBrain ImagingMechanism of ActionBiomarkersAgingEmotional ProcessingObservational StudyVeteransSafetyTranscriptomicsObservational StudySuicidal IdeationfMRI Neurofeedback
